JP2014526448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526448A5 JP2014526448A5 JP2014528897A JP2014528897A JP2014526448A5 JP 2014526448 A5 JP2014526448 A5 JP 2014526448A5 JP 2014528897 A JP2014528897 A JP 2014528897A JP 2014528897 A JP2014528897 A JP 2014528897A JP 2014526448 A5 JP2014526448 A5 JP 2014526448A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- inflammation
- ester
- amide
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000002148 esters Chemical class 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 7
- 150000001408 amides Chemical class 0.000 claims 7
- 230000004054 inflammatory process Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- -1 fluocortron Chemical compound 0.000 claims 6
- 208000019693 Lung disease Diseases 0.000 claims 5
- KIIBBJKLKFTNQO-WHFBIAKZSA-N 5-hydroxyectoine Chemical compound CC1=N[C@H](C(O)=O)[C@@H](O)CN1 KIIBBJKLKFTNQO-WHFBIAKZSA-N 0.000 claims 4
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003246 corticosteroid Substances 0.000 claims 4
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 claims 4
- 210000003714 granulocyte Anatomy 0.000 claims 4
- 230000002424 anti-apoptotic effect Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 201000010001 Silicosis Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 210000000222 eosinocyte Anatomy 0.000 claims 2
- 210000003237 epithelioid cell Anatomy 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 210000003630 histaminocyte Anatomy 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 230000003448 neutrophilic effect Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 230000036427 bronchial hyperreactivity Effects 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 229960002842 clobetasol Drugs 0.000 claims 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 1
- 229960001146 clobetasone Drugs 0.000 claims 1
- XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 claims 1
- 238000013329 compounding Methods 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 229960001145 deflazacort Drugs 0.000 claims 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 claims 1
- 229960002593 desoximetasone Drugs 0.000 claims 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960002011 fludrocortisone Drugs 0.000 claims 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims 1
- 229960003469 flumetasone Drugs 0.000 claims 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 claims 1
- 229940043075 fluocinolone Drugs 0.000 claims 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 1
- 229960000785 fluocinonide Drugs 0.000 claims 1
- 229960005355 fluocortin Drugs 0.000 claims 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960002383 halcinonide Drugs 0.000 claims 1
- 229960002475 halometasone Drugs 0.000 claims 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 239000013618 particulate matter Substances 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960001487 rimexolone Drugs 0.000 claims 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011113059A DE102011113059A1 (de) | 2011-09-09 | 2011-09-09 | Therapeutische Anwendungen von Ectoin |
| DE102011113059.8 | 2011-09-09 | ||
| PCT/EP2012/003757 WO2013034299A1 (de) | 2011-09-09 | 2012-09-07 | Therapeutische anwendungen von ectoin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017133770A Division JP6396544B2 (ja) | 2011-09-09 | 2017-07-07 | エクトインの治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526448A JP2014526448A (ja) | 2014-10-06 |
| JP2014526448A5 true JP2014526448A5 (enExample) | 2015-11-05 |
| JP6250542B2 JP6250542B2 (ja) | 2017-12-20 |
Family
ID=47115708
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528897A Active JP6250542B2 (ja) | 2011-09-09 | 2012-09-07 | エクトインの治療的使用 |
| JP2017133770A Active JP6396544B2 (ja) | 2011-09-09 | 2017-07-07 | エクトインの治療的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017133770A Active JP6396544B2 (ja) | 2011-09-09 | 2017-07-07 | エクトインの治療的使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140315869A1 (enExample) |
| EP (2) | EP2753330B1 (enExample) |
| JP (2) | JP6250542B2 (enExample) |
| CN (1) | CN103857394A (enExample) |
| BR (1) | BR112014005414A2 (enExample) |
| CA (1) | CA2848010A1 (enExample) |
| DE (1) | DE102011113059A1 (enExample) |
| ES (2) | ES2657907T3 (enExample) |
| IN (1) | IN2014CN02458A (enExample) |
| PL (2) | PL2753330T3 (enExample) |
| RU (1) | RU2648475C2 (enExample) |
| WO (1) | WO2013034299A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160106747A1 (en) * | 2008-01-30 | 2016-04-21 | Bitop Ag | Treating postoperative mechanical stress with an ectoine |
| DE102008039231A1 (de) | 2008-08-22 | 2010-02-25 | Bitop Ag | Verwendung von Glucosylglycerol |
| DE102014007423A1 (de) * | 2014-05-22 | 2015-11-26 | Bitop Ag | Zusammensetzung zur Behandlung des Auges |
| DE102014113781A1 (de) * | 2014-09-23 | 2016-03-24 | Bitop Ag | Solut und Solutgemisch sowie eine Zusammensetzung enthaltend mindestens ein Solut zur Verwendung bei der Prävention oder Behandlung von durch Schwebstaub verursachter kosmetischer oder pathologischer Effloreszenzen |
| DE102015121050A1 (de) * | 2015-12-03 | 2017-06-08 | Bitop Ag | Kompatibles Solut oder Solutgemisch zur Verwendung bei der Prävention oder Behandlung von Krankheiten mit Barrieredefekten in Epithelgeweben |
| DE102016104470A1 (de) | 2016-03-11 | 2017-09-14 | Bitop Ag | Zusammensetzung zur Förderung der Aktivität von Sirtuinen |
| CN111936142A (zh) * | 2018-04-05 | 2020-11-13 | 株式会社资生堂 | Asmt表达促进剂 |
| CN114425056A (zh) * | 2020-10-14 | 2022-05-03 | 宁波希诺赛生物科技有限公司 | 一种用于改善哮喘的干细胞外泌体组合物 |
| CN116570525B (zh) * | 2023-06-30 | 2025-09-23 | 华熙生物科技股份有限公司 | 一种具有舒缓功效的组合物及其制备方法和用途 |
| PL448505A1 (pl) * | 2024-05-08 | 2025-11-12 | Szkoła Główna Gospodarstwa Wiejskiego w Warszawie | Kompozycja o właściwościach barierowych i wirusobójczych wobec koronawirusów, zwłaszcza SARS-CoV-2, sposób jej otrzymywania i zastosowanie |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4244580A1 (de) | 1992-12-31 | 1994-07-07 | Galinski Erwin A | Verfahren zur in vivo Gewinnung von Inhaltsstoffen aus Zellen |
| DE4342560A1 (de) * | 1993-12-14 | 1995-06-22 | Marbert Gmbh | Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten |
| NZ512383A (en) * | 1998-12-22 | 2003-05-30 | Univ North Carolina | Use of osmotic agents in the treatment of airway diseases and for the delivery of airway drugs |
| ATE247981T1 (de) * | 1999-06-12 | 2003-09-15 | Bitop Ag | Proteinenthaltende pharmazeutische zubereitung |
| DE10006578C2 (de) * | 2000-02-14 | 2002-10-31 | Bitop Ag | Verwendung von kompatiblen Soluten als Inhibitoren des enzymatischen Abbaus von makromolekularen Biopolymeren |
| DE10065986A1 (de) | 2000-12-21 | 2002-07-11 | Bitop Gmbh | Kompatible Solute als Stabilisatoren für Impfstoffe und Vakzine |
| DE10330243A1 (de) | 2003-07-03 | 2005-01-20 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis |
| DE10330768A1 (de) | 2003-07-07 | 2005-02-24 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung |
| DE102006056766A1 (de) | 2006-12-01 | 2008-06-05 | Bitop Ag | Verwendung von kompatiblen Soluten |
| DE102007040615A1 (de) * | 2007-08-27 | 2009-03-05 | Bitop Ag | Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen |
-
2011
- 2011-09-09 DE DE102011113059A patent/DE102011113059A1/de active Pending
-
2012
- 2012-09-07 EP EP12780649.5A patent/EP2753330B1/de active Active
- 2012-09-07 PL PL12780649T patent/PL2753330T3/pl unknown
- 2012-09-07 CN CN201280049557.3A patent/CN103857394A/zh active Pending
- 2012-09-07 WO PCT/EP2012/003757 patent/WO2013034299A1/de not_active Ceased
- 2012-09-07 IN IN2458CHN2014 patent/IN2014CN02458A/en unknown
- 2012-09-07 PL PL17189829T patent/PL3287131T3/pl unknown
- 2012-09-07 EP EP17189829.9A patent/EP3287131B1/de active Active
- 2012-09-07 RU RU2014113906A patent/RU2648475C2/ru not_active IP Right Cessation
- 2012-09-07 CA CA2848010A patent/CA2848010A1/en not_active Abandoned
- 2012-09-07 JP JP2014528897A patent/JP6250542B2/ja active Active
- 2012-09-07 ES ES12780649.5T patent/ES2657907T3/es active Active
- 2012-09-07 ES ES17189829T patent/ES2795879T3/es active Active
- 2012-09-07 BR BR112014005414A patent/BR112014005414A2/pt not_active Application Discontinuation
- 2012-09-07 US US14/343,017 patent/US20140315869A1/en not_active Abandoned
-
2017
- 2017-07-07 JP JP2017133770A patent/JP6396544B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526448A5 (enExample) | ||
| RU2014113906A (ru) | Терапевтическое применение эктоина | |
| JP2017197569A5 (enExample) | ||
| JP2012532889A5 (enExample) | ||
| HRP20200495T1 (hr) | Sastavi za liječenje gastrointestinalne upale | |
| JP2014510064A5 (enExample) | ||
| JP2017019845A5 (enExample) | ||
| JP2008297309A5 (enExample) | ||
| JP6501774B2 (ja) | Ｍａｂａ化合物およびコルチコステロイドを含む組合せ剤 | |
| JP2012528792A5 (enExample) | ||
| JP2016510012A (ja) | Ｍａｂａ化合物およびコルチコステロイドを含む組合せ剤 | |
| JP2016510012A5 (enExample) | ||
| JP2006518376A5 (enExample) | ||
| RU2017142694A (ru) | Водная суспензия, содержащая наночастицы глюкокортикостероида | |
| RU2013128607A (ru) | Фармацевтические составы, содержащие кортикостероиды, для топикального применения | |
| JP2015506983A5 (enExample) | ||
| HRP20161279T1 (hr) | Kombinirani preparati s antagonistom citokina i ortikosteroidom | |
| JP2018529767A (ja) | 自己免疫疾患及び自己炎症疾患の治療方法 | |
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| JP2018537453A5 (enExample) | ||
| JP2016510765A5 (enExample) | ||
| JP2014516962A5 (enExample) | ||
| JP2014501785A (ja) | ステロイドおよびグルココルチコイド受容体アンタゴニスト組合せ治療 | |
| US20120245552A1 (en) | Combination Therapy | |
| JP2006518382A5 (enExample) |